8-K current report · filed Aug 19, 2026

TuHURA Biosciences, Inc./NV (HURA) 8-K Current Report: August 19, 2026

Item 5.07Item 3.02HURA overview

Short answer

TuHURA Biosciences, Inc./NV (HURA) filed an 8-K current report with the SEC on August 19, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 3.02 (Unregistered Sales of Equity Securities). Stockholders approved issuance of 1,878,287 Loan Fee Shares to Parkview.

TuHURA Biosciences, Inc./NV 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.02 · Unregistered Sales of Equity Securities

  • Stockholders approved issuance of 1,878,287 Loan Fee Shares to Parkview
  • Shares compensate Parkview under the $50 million revolving credit facility
  • Issuance becomes effective following approval, increasing shares outstanding and potential dilution
  • Private placement limited to accredited investor under Section 4(a)(2) and/or Regulation D Rule 506

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • Six director nominees elected to serve through the 2027 annual meeting, with 43,034,024 shares represented
  • Nasdaq approval authorizes issuance of 1,878,287 common shares under the Fee Letter, creating potential dilution
  • Executive compensation approved on an advisory basis, with 26,125,280 votes for and 2,484,951 against
  • Three-year frequency selected for future executive compensation votes
  • Cherry Bekaert LLP ratified as independent auditor for fiscal year ending December 31, 2026, with 42,911,888 votes for

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TuHURA Biosciences, Inc./NV 8-K filings

Get the next HURA 8-K as it lands

Follow HURA for push alerts, or ask the research agent what this filing means.